Design Therapeutics, Inc. - Common Stock (DSGN)

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / Common Stock
Shares outstanding
57,159,091
Total 13F shares
30,700,544
Share change
-951,323
Total reported value
$123,722,440
Put/Call ratio
100%
Price per share
$4.03
Number of holders
88
Value change
-$2,844,064
Number of buys
36
Number of sells
49

Institutional Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q1 2024

As of 31 Mar 2024, Design Therapeutics, Inc. - Common Stock (DSGN) was held by 88 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 30,700,544 shares. The largest 10 holders included SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, BlackRock Inc., BAKER BROS. ADVISORS LP, TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, Almitas Capital LLC, BML Capital Management, LLC, CITADEL ADVISORS LLC, and STATE STREET CORP. This page lists 88 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.